Mobocertinib Succinate
Generic Name: mobocertinib succinate
Manufactured by TAKEDA PHARMS USA. Dosage form: CAPSULE. Route: ORAL. Active ingredients: MOBOCERTINIB SUCCINATE (EQ 40MG BASE). Application: NDA215310.
Overview
Manufactured by TAKEDA PHARMS USA. Dosage form: CAPSULE. Route: ORAL. Active ingredients: MOBOCERTINIB SUCCINATE (EQ 40MG BASE). Application: NDA215310.
Dosage
Available as capsule for oral use.
Related Medications
Xenon Xe 129 Hyperpolarized
xenon xe 129 hyperpolarized
Hyperpolarized Contrast Agent [EPC]
11 DESCRIPTION XENOVIEW (xenon Xe 129 hyperpolarized) is a hyperpolarized contrast agent produced on site by the HPX Hyperpolarization System from the isotopically enriched Xenon Xe 129 Gas Blend. The Gas Blend cylinder distributed by Polarean contains xenon (1% total; > 80% isotopic purity Xe 129), nitrogen, NF (10%), and helium, NF (89%). The active pharmaceutical ingredient in XENOVIEW is hyperpolarized xenon Xe 129.
Carboxymethylcellulose Sodium, Glycerin, Polysorbate 80
carboxymethylcellulose sodium, glycerin, polysorbate 80
Non-Standardized Chemical Allergen [EPC]
Purpose Eye lubricant Eye lubricant Eye lubricant
Technetium Tc 99m Sestamibi
technetium tc 99m sestamibi
11. DESCRIPTION Each 10 mL vial contains a sterile, non-pyrogenic, lyophilized mixture of: Tetrakis (2-methoxy isobutyl isonitrile) Copper (I) tetrafluoroborate – 1 mg Sodium Citrate Dihydrate - 2.6 mg L-Cysteine Hydrochloride Monohydrate – 1 mg Mannitol - 20 mg Stannous Chloride, Dihydrate, minimum (SnCl 2 •2H 2 O) - 0.025 mg Stannous Chloride, Dihydrate (SnCl 2 •2H 2 O) - 0.075 mg Tin Chloride (stannous and stannic) Dihydrate, maximum (as SnCl 2 •2H 2 O) - 0.086 mg Prior to lyophilization the.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.